Kolitis-assoziierte Karzinome, Prävention und Früherkennung

Zusammenfassung

Patienten mit chronisch entzündlichen Darmerkrankungen haben ein erhöhtes Risiko im Verlaufe ihrer Erkrankung ein kolorektales Karzinom (CRC) zu entwickeln. Das Risiko an einem Kolonkarzinom zu erkranken ist bei Patienten mit Colitis ulcerosa (CU) bis zu dreifach höher als in der Normalbevölkerung. Unter der Voraussetzung, dass das Kolon befallen ist, gelten ähnliche Risikofaktoren auch für den M. Crohn (MC) [1], die Datenlage ist jedoch deutlich spärlicher.
Das Risiko hängt im Wesentlichen von der Dauer und Ausdehnung der Erkrankung ab [2] [3] [4] [5], die Mortalität bei Patienten mit chronisch entzündlichen Darmerkrankungen ist dabei höher als bei Patienten mit sporadischem kolorektalen Karzinom [6]. Insbesondere jüngere Patienten mit Colitis ulcerosa oder Crohn-Kolitis über 10 Jahre andauernder Krankheitsgeschichte und ausgedehntem Befall haben ein hohes relatives Risiko (Alter 20-39 Jahre, RR 22) ein Karzinom zu entwickeln. Als Risikofaktoren sind weiterhin lange Krankheitsdauer, gleichzeitige geringe Krankheitsaktivität, frühe Erkrankung, gleichzeitig bestehende primär sklerosierende Cholangitis, Stenosen und der Nachweis einer „Backwash Ileitis” etabliert. Das Fehlen einer adäquaten Überwachung von Risikopatienten scheint ebenso wie eine unzureichende antientzündliche Therapie, ein Folsäuremangel und evtl. sogar ein Nichtraucherstatus das Risiko eines Kolitis-assoziierten Karzinoms (Ulcerative Colitis Associated Colorectal Cancer UCACRC) zu erhöhen [2] [3] [4] [7] [8] [9] [10] [11] [12]. Es gilt allgemein als akzeptiert, dass Dysplasien die Vorstufen des Kolitis-assoziierten Karzinoms bilden und als solche als Marker für ein Karzinomrisiko darstellen. Obwohl eindeutige Studien zum eigentlichen Nutzen fehlen wird daher eine Überwachung von Patienten mit länger andauernden chronisch entzündlichen Darmerkrankungen zur Früherkennung von Dysplasien und Karzinomen empfohlen [13] [14]. Während diese Strategien zur Prävention des kolorektalen Karzinoms heute durch Studien recht gut belegt sind, ist die Datenlage bezüglich einer Überwachungsstrategie zur Prävention des Colitis ulcerosa-assoziierten Karzinoms wesentlich schlechter. So bestehen große Unsicherheiten, welche Patientengruppe überwacht werden muss und wie eine solche Überwachung aussehen sollte [15]. Generell wird empfohlen, alle Patienten mit früher Manifestation, langjährigem und ausgedehntem Befall etwa 8-10 Jahre nach Erstmanifestation in ein Überwachungsprogramm einzuschließen. Dieses Programm sollte derzeit eine hohe Koloskopie in ein- bis zweijährlichen Intervallen mit der Entnahme von Stufenbiopsien zur frühzeitigen Entdeckung von Epitheldysplasien beinhalten. Besonderer Wert sollte dabei auf reichliche bioptische Probenentnahmen z. B. alle 10 cm des Darms und die konsequente Anwendung pathologischer Dysplasie-Kriterien z. B. nach dem IBD-DMSG-Standard gelegt werden [16] [17]. Bei Nachweis von highgrade-Dysplasien und DALM ist eine Proktokolektomie zu empfehlen, bei Nachweis von low-grade-Dysplasien ist zumindest die Überwachung zu intensivieren und auch hier ggfs. eine Proktokolektomie zu erwägen.

Abstract

Patients with chronic inflammatory bowel disease have a higher risk of developing colorectal carcinoma (CRC) during the course of their disease. The risk of colon carcinoma is up to three times higher in patients with ulcerative colitis than in the normal population. When the colon is affected, similar risk factors also hold for patients with Crohn's disease (CD) [1] although markedly few data are available.
The risk depends principally on the duration and extent of the disease [2] [3] [4] [5], with the mortality being higher for patients with chronic inflammatory bowel disease than for patients with sporadic colorectal carcinomas [6]. In particular, younger patients with ulcerative colitis or Crohn's colitis with a duration of disease of more than 10 years and extensive attack have a high relative risk of developing a carcinoma (age 20-39 years, RR 22). A long duration of disease with concomitant low disease activity, early onset, a simultaneously existing primary sclerorising cholangitis, stenoses, and the detection of backwash ileitis are still considered as risk factors. The lack of an adequate control of risk patients as well as an unsatisfactory anti-inflammation therapy, a folic acid deficiency and possibly, also non-smoking status, appear to increase the risk of colitis-associated carcinoma (ulcerative colitis associated colorectal cancer, UCACRC) [2] [3] [4] [7] [8] [9] [10] [11] [12]. It is generally accepted that dysplasias represent the precursors of colitis-associated carcinoma and as such constitute a marker for the carcinoma risk. Although unambiguous studies are lacking, the close monitoring for the early detection of dysplasias and carcinomas in patients with long-duration chronic inflammatory bowel diseases is recommended [13] [14]. Although these strategies for the prevention of colorectal carcinoma are now well-founded by studies, the available data on monitoring strategies for the prevention of ulcerative colitis-associated carcinomas are much less extensive. Thus, there are large differences of opinion as to which patient groups should be monitored and what such as monitoring scheme should look like [15]. It is generally recommended to include all patients with long-duration and extensive attack in a monitoring program at about 8-10 years after the first manifestation. This program should involve a high coloscopy with serial biopsies for the early detection of epithelial dysplasias at one to two year intervals. Particular attention should be paid to obtaining sufficient biopsy samples, e. g., at about every 10 cm along the bowel, and the consequent application of pathological dysplasia criteria, e. g., according to those set out in the IBD-DMSG standard [16] [17]. On detection of high-grade dysplasia and DALM, a proctocolectomy is recommended, on detection of low-grade dysplasias at least the monitoring should be intensified and a proctocolectomy considered.

Colitis ulcerosa - Kolorektale Karzinome - Prävention - Diagnose

Ulcerative colitis - colorectal carcinoma - prevention - diagnosis

Literatur

• 1 Sachar D B. Cancer in Crohn's disease. Sispelling the myths.  Gut. 1994;  35 651-655
• 2 Rosenqvist H, Ohrling H, Lagercrantz R, Edling N. Ulcerative colitis and carcinoma coli.  Lancet. 1950;  1 906-908
• 3 Edwards F C, Truelove S C. Course and prognosis of ulcerative colitis. IV: Carcinoma of colon.  Gut. 1964;  5 1-22
• 4 Connell W R, Leonard-Jones J E, Williams C B. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.  Gastroenterology. 1994;  107 934-944
• 5 Devroede G J, Taylor W F, Sauer W G, Jackman R J, Stickler G B. Cancer risk and life expectancy of children with ulcerative colitis.  N Engl J Med. 1971;  285 17-21
• 6 Ekbom A. Cancer in inflammatory bowel disease. In: Caprilli E (ed). Inflammatory bowel disease. Schattauer, Stuttgart 1997; 91-97
• 7 Ekbom A, Helmick C, Zack M, Adami H O. Ulcerative colitis and colorectal cancer: A population-based study.  N Engl J Med. 1990;  323 1228-1233
• 8 Weedon D D, Shorter R G, Illstrup D M, Huizenga K A, Taylor W F. Crohn's disease and cancer.  N Engl J Med. 1973;  289 1099-1103
• 9 Softley A, Clamp S E, Watkinson G, Bouchier I A, Myren J, deDombal F T. The natural history of inflammatory bowel disease: Has there been a change in the last 20 years?.  Scand J Gastroenterol Suppl. 1988;  144 20-23
• 10 Richards M E, Rickert R R, Nance F C. Crohn's disease-associated carcinoma: A poorly recognized complication of inflammatory bowel disease.  Ann Surg. 1989;  209 764-773
• 11 Ekbom A, Helmick C, Zack M, Adami H O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.  Lancet. 1990;  336 357-359
• 12 Heuschen U A, Hinz U, Allemeyer E H, Stern J, Lucas M, Autschback F, Herfarth C, Heuschen G. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis.  Gastroenterology. 2001;  120 747-841
• 13 Kornbluth A, Sachar D B. Ulcerative colitis practice guidelines in adults.  Am J Gastroenterol. 1997;  92 204-211
• 14 Peppercorn M A, Odze R D. Colorectal cancer surveillance in inflammatory bowel disease. UptoDate version11.03. www.uptodate.com
• 15 Snapper S B, Syngal S, Friedman L S. Ulcerative colitis and colon cancer: more controversy than clarity.  Dig Dis. 1998;  16 81-87
• 16 Riddell R H, Goldman H, Ransohoff D F. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application.  Hum Pathol. 1983;  14 931-968
• 17 Connell W R, Lennard-Jones J E, Williams C B, Falbot I C, Price A B, Wilkinson K H. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.  Gastroenterology. 1994;  107 934-944
• 18 Gyde S N, Prior P, Allan R N. et al . Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centers.  Gut. 1988;  29 206-217
• 19 Lennard-Jones J E. Cancer risk in ulcerative colitis: Surveillance or surgery.  Br J Surg. 1985;  72 (Suppl) 84-86
• 20 Lofberg R, Brostrom O, Karlen P. Colonoscopic surveillance in long-standing total ulcerative colitis - a 15-year follow-up study.  Gastroenterology. 1990;  99 1021-1031
• 21 Collins R H, Feldman M, Fordtran J S. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review.  N Engl J Med. 1987;  316 1654-1658
• 22 Katzka I, Brody R S, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis: Experience from a private practice.  Gastroenterology. 1983;  85 22-29
• 23 Mir-Madjlessi S H, Farrer R G, Easley K A, Beck G J. Colorectal and extracolonic malignancy in ulcerative colitis.  Cancer. 1986;  58 1569-1574
• 24 Lennard-Jones J E, Melville D M, Morson B C, Ritchie J K, Williams C B. Precancer and cancer in extensive ulcerative colitis: Findings among 401 patients over 22 years.  Gut. 1990;  31 800-806
• 25 Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis.  Gastroenterology. 1992;  103 1444-1451
• 26 Greenstein A J, Sachar D B, Smith H. et al . Cancer in universal and left-sided ulcerative colitis: Factors determining risk.  Gastroenterology. 1979;  77 290-294
• 27 Nugent F W, Haggitt R C, Gilpin P A. Cancer surveillance in ulcerative colitis.  Gastroenterology. 1991;  100 1241-1248
• 28 Levin B. Inflammatory bowel disease and colon cancer.  Cancer. 1992;  70 1313-1316
• 29 Pardi D S, Loftus E V, Kremers W K, Keach J, Lindor K D. Ursodesoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893
• 30 Rubio C A, Befrits R. Colorectal adenocarcinoma in Crohn's disease: A retrospective histologic study.  Dis Colon Rectum. 1997;  40 1072-1078
• 31 Friedman S, Rubin P H, Bodian C, Goldstein E, Harpaz N, Present D H. Screening and Surveillance Colonoscopy in Chronic Crohn's Colitis.  Gastroenterology. 2001;  120 820-826
• 32 Greenstein A J, Sachar D B, Smith H, Janowitz H D, Aufses A H. A comparison of cancer risk in Crohn's disease and ulcerative colitis.  Cancer. 1981;  48 2742-2745
• 33 Gyde S N, Prior P, Macartney J C, Thompson H, Waterhouse J A, Allan R N. Malignancy in Crohn's disease.  Gut. 1980;  21 1024-1029
• 34 Choi P M, Zelig M P. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications for carcinogenesis and prevention.  Gut. 1994;  35 950-954
• 35 Gillen C D, Walmsley R S, Prior R, Andrews H A, Allan R N. Ulcerative colitis and Crohn's disease: A comparison of the colorectal cancer risk in extensive colitis.  Gut. 1994;  35 1590-1592
• 36 Itzkowitz S H, Greenwald B, Meltzer S J. Colon carcinogenesis in inflammatory bowel disease.  Inflamm Bowel Dis. 1995;  1 142-146
• 37 Butt J H, Konishi F, Morson B C, Lennard-Jones J E, Ritchie J K. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis.  Dig Dis Sci. 1983;  28 18-26
• 38 Connell W R, Sheffield J P, Kamm M A, Ritchie J K, Hawley P R, Lennard-Jones J E. Lower gastrointestinal malignancy in Crohn's disease.  Gut. 1994;  35 347-352
• 39 Hamilton S R. Colorectal carcinoma in patients with Crohn's disease.  Gastroenterology. 1985;  89 398-407
• 40 Petras R E, Mir-Madjlessi S H, Farmer R G. Crohn's disease and intestinalcarcinoma: A report of 11 cases with emphasis on associated epithelial dysplasia.  Gastroenterology. 1987;  93 1307-1314
• 41 Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis.  Cell. 1990;  61 759-767
• 42 Vogelstein B, Fearon E R, Hamilton S R. et al . Genetic alterations during colorectal-tumor development.  N Engl J Med. 1988;  319 525-535
• 43 Burmer G C, Levine D S, Kulander B G, Haggitt R C, Rubin C E, Rabinovitch P S. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma.  Gastroenterology. 1990;  99 416-420
• 44 Baker S J, Preisinger A C, Jessup J M. et al . p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.  Cancer Res. 1990;  50 7717-7722
• 45 Burmer G C, Rabinovitch P S, Haggitt R C. et al . Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele.  Gastroenterology. 1992;  103 1602-1610
• 46 Levin B. Ulcerative colitis and colon cancer: biology and surveillance.  J Cell Biochem. 1992;  16 (Suppl) 47-50
• 47 Morson B C, Pang L SC. Rectal biopsy as an aid to cancer control in ulcerative colitis.  Gut. 1967;  8 423-434
• 48 Melville D M, Jass J R, Morson B C. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome.  Hum Pathol. 1989;  20 1008-1014
• 49 Bernstein C N, Shanahan F, Weinstein W M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?.  Lancet. 1994;  343 71-74
• 50 Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B. Colonoscopic surveillance in long-standing total ulcerative colitis: A 15-year follow-up study.  Gastroenterology. 1990;  99 1021-1031
• 51 Fresko D, Lazarus S S, Dotan J, Reingold M. Early presentation of carcinoma of the small bowel in Crohn's disease (‘Crohn's carcinoma’). Case reports and review of the literature.  Gastroenterology. 1982;  82 783-789
• 52 Korelitz B L, Lauwers G Y, Sommers S C. Rectal mucosal dysplasia in Crohn's disease.  Gut. 1990;  31 1382-1386
• 53 Warren R, Barwick K W. Crohn's colitis with adenocarcinoma and dysplasia. Report of a case and review of 100 small and large bowel resections for Crohn's disease to detect incidence of dysplasia.  Am J Surg Pathol. 1983;  7 151-159
• 54 Albert M B, Nochomovitz L E. Dysplasia and cancer surveillance in inflammatory bowel disease.  Gastroenterol Clin North Am. 1989;  18 8397
• 55 Axon A T. Cancer surveillance in ulcerative colitis: A time for reappraisal.  Gut. 1995;  36 801
• 56 Brostrom O, Lofberg R, Ost A, Reichar H. Cancer surveillance of patients with long-standing ulcerative colitis: A clinical, endoscopic, and histological study.  Gut. 1986;  27 1408-1413
• 57 Manning A P, Bulgim O R, Dixon M F, Axon A T. Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease.  Gut. 1987;  28 1489-1494
• 58 Ransohoff D F, Riddell R H, Levin B. Ulcerative colitis and colonic cancer: Problems in assessing the diagnostic usefulness of mucosal dysplasia.  Dis Colon Rectum. 1985;  28 383-388
• 59 Taylor B A, Pemberton J H, Carpenter H A. et al . Dysplasia in chronic ulcerative colitis: Implications for colonoscopic surveillance.  Dis Colon Rectum. 1992;  35 950-956
• 60 Melville D M, Jass J R, Shepherd N A. et al . Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations.  Gastroenterology. 1988;  95 668-675
• 61 Dixon M F, Brown L J, Gilmour H M. et al . Observer variation in the assessment of dysplasia in ulcerative colitis.  Histopathology. 1988;  13 385-387
• 62 Gorfine S R, Bauer J J, Harris M T, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?.  Dis Colon Rectum. 2000;  43 1575-1581
• 63 Blackstone M O, Riddell R H, Rogers B H, Levin B. Dysplasia associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: An indication for colectomy.  Gastroenterology. 1981;  80 366-374
• 64 Schneider A, Stolte M. Clinical and pathomorphological findings in patients with colorectal carcinoma complicating ulcerative colitis.  Z Gastroenterol. 1993;  31 192-197
• 65 Konishi F, Wakasa H, Kino I. Histological classification of the neoplastic changes arising in ulcerative colitis: a new proposal in Japan.  J Gastroenterol. 1985;  30 (Suppl 8) 20-24
• 66 Tytgat G N, Dhir V, Gopinath N. Dysplasien in flacher Mukosa. Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease.  Eur J Cancer. 1995;  31 1174-1177
• 67 Suzuki K, Muto T, Shinozaki M, Yokoyama T, Matsuda K, Masaki T. Differential diagnosis of dysplasia-associated lesion or mass and coincidental adenoma in ulcerative colitis.  Dis Colon Rectum. 1998;  41 322-327
• 68 Odze R D. Adenomas and adenoma-like DALMS in chronic ulcerative colitis: A clinical, pathological and molecular review.  Am J Gastroenterol. 1999;  94 1746-1750
• 69 Engelsgjerd M, Farraye F A, Odze R D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.  Gastroenterology. 1999;  117 1288-1294
• 70 Rubin P H, Friedman S, Harpaz N. et al . Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps.  Gastroenterology. 1999;  117 1295-1230
• 71 Odze R D, Brown C A, Hartmann C J, Noffsinger A E, Fogt F. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas.  Am J Surg Pathol. 2000;  24 1209-1216
• 72 Torres C, Antonioli D, Odze R D. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients.  Am J Surg Pathol. 1998;  22 275-284
• 73 Morin P J, Sparks A B, Korinek V. et al . Activation of B-catenin-TcF signaling in colon cancer by mutations in B-catenin or APC.  Science. 1997;  275 1787-1790
• 74 Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis B. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.  Proc Natl Acad Sci USA. 1995;  92 3046-3050
• 75 Rubin C E, Haggitt R C, Burmer G C, Brentnall T A, Stevens A C, Levine D S, Dean P J, Kimmey M, Perera D R, Rabinovitch P S. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis.  Gastroenterology. 1992;  103 1611-1620
• 76 Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.  Gastroenterology. 2004;  126 451-459
• 77 Woolrich A J, Da Silva B I, Korelitz B. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.  Gastroenterology. 1992;  103 431-438
• 78 Taylor B A, Pemberton J H, Carpenter H A. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance.  Dis Colon Rectum. 1992;  35 950-956
• 79 Allen D C, Hamilton P W, Watt P C, Biggart J D. Morphometrical analysis in ulcerative colitis with dysplasia and carcinoma.  Histopathology. 1987;  11 913-923
• 80 Allen D C, Hamilton P W, Watt P C, Biggart J D. Architectural morphometry in ulcerative colitis with dysplasia.  Histopathology. 1988;  12 611-621
• 81 Lennard-Jones J E, Morson B C, Ritchie J K. et al . Cancer in colitis: Assessment of the individual risk by clinical and histological criteria.  Gastroenterology. 1977;  73 1280-1287
• 82 Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis.  Gastroenterology. 1995;  108 1361-1370
• 83 Choi P M, Nugent F W, Schoetz D J, Silverman M L, Haggitt R C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.  Gastroenterology. 1993;  105 418-424
• 84 Provenzale D, Wong J B, Onken J E, Lipscomb J. Performing a cost-effectiveness analysis: Surveillance of patients with ulcerative colitis.  Am J Gastroenterol. 1998;  93 872-880
• 85 Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress?.  Gastroenterology. 1994;  107 1196-1199
• 86 Ullman T A, Loftus E V, Kakar S, Burgart L J, Sandborn W J, Tremaine W J. The fate of low grade dysplasia in ulcerative colitis.  Am J Gastroenterol. 2002;  97 922-927
• 87 Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson P G, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study.  Gut. 1998;  42 711-714
• 88 Lashner B A, Kane S V, Hanauer S B. Colon cancer surveillance in chronic ulcerative colitis: Historical cohort study.  Am J Gastroenterol. 1990;  85 1083-1087
• 89 Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B. DNA aneuploidy in ulcerative colitis: Reproducibility, topographic distribution, and relation to dysplasia.  Gastroenterology. 1992;  102 1149-1154
• 90 Itzkowitz S H, Young E, Dubois D. et al . Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: A retrospective case-control study.  Gastroenterology. 1996;  110 694-704
• 91 Greenwald B D, Harpaz N, Yin J. et al . Loss of heterozygosity affecting the p53, Rh, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis.  Cancer Res. 1992;  52 741-745
• 92 Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait. Carcinoma and DNA aneuploidy in Crohn's colitis: A histological and flow cytometric study.  Gut. 1991;  32 900-904
• 93 Tung B, Emond M J, Haggitt R C. et al . Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.  Ann Intern Med. 2001;  134 89-95
• 94 Kiesslich R, Fritsch J, Holtmann M. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 880-888
• 95 Hontecillas R, Wannemeulher M J, Zimmerman D R. et al . Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid.  J Nutr. 2002;  132 2019-2027
• 96 Lashner B A. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis.  J Cancer Res Clin Oncol. 1993;  119 549-554
• 97 Lashner B A, Heidenreich P A, Su G L, Kane S V, Hanauer S B. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study.  Gastroenterology. 1989;  97 255-259
• 98 Lashner B A, Provencher K S, Seidner D L, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.  Gastroenterology. 1997;  112 29-32
• 99 Courtney E DJ, Melville D M, Leicester R J. Review article: chemoprevention of colorectal cancer.  Aliment Pharmacol Ther. 2004;  19 1-24
• 100 Ryan B M, Russel M G, Langholz E, Stockbrugger R W. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.  Am J Gastroenterol. 2003;  98 1682-1687
• 101 Eaden J. Review article: The data supporting sa role for aminosalycylates in the prevention of colorectal cancer in patients.  Aliment Pharmacol Ther. 2003;  18 (Suppl 2) 15-21
• 102 Eaden J A, Mayberry J F. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.  Gut. 2002;  51 (Suppl 5) 10
• 103 Hanauer S B, Meyers S. Practice guidelines. Management of Crohn's disease in adults.  Am J Gastroenterol. 1997;  92 559-566